Researchers from Kennedy Krieger Institute, University of Rochester Medicine and five other institutions released a new publication detailing how master protocol trials could change the future of rare disease research. Using master protocol trials to research rare conditions could decrease costs, improve testing efficiency and capacity, and expedite the delivery of treatments to those facing a rare disease diagnosis.